CORRECTED – Acino shares dip after Norwegian court ruling

(Corrects 4 mln Sfr to 4 mln euros in bullet pts, lead)

* Acino may pay 4 mln euros after patent infringement ruling

* To be offset by one-off gain to iclaprim acquisition

* Acino confirms 2010 outlook

* Shares fall 2 pct, underperform weaker Swiss market

ZURICH, Dec 27 (BestGrowthStock) – Shares in Swiss generic drugmaker
Acino (ACIN.S: ) slipped some 2 percent on Monday on news the
group may have to pay 4 million euros ($5.25 million) after a
court ruled one of its drugs infringed a patent.

At 1112 GMT, shares in the group, which have already fallen
over 42 percent so far this year, were trading 1.8 percent lower
at 90.55 francs, underperforming the broader Swiss market.

A Norwegian court of appeal ruled last week Acino’s generic
version of Mundipharma’s pain drug Oxycontin infringed the
patent. The decision also means Acino will have to withdraw its
oxycodon product from the Norwegian market.

Acino said it planned to appeal the decision.

The group also said it was still sticking to its 2010
outlook for a positive full-year result after a slightly better
performance in the fourth quarter than in the third quarter.

Acino also said a one-off contribution to net profit from
the acquisition of the iclaprim business should compenstate for
provisions after the Norwegian ruling.

Acino bought iclaprim, a new intravenous antibiotic used to
treat MRSA strains resistant to many antibiotics, from Arpida
last year.

“We estimate total annual sales of oxycodon in the Norwegian
market to be below 1 million euros p.a. and hence leave our
sales assumptions beyond 2010 unchanged,” Vontobel analyst Carla
Baenziger said. “Overall our earnings per share assumptions for
2010 remain unchanged.”

Acino has had a tough year, hit by a recall of batches of
its top-selling drug clopidogrel, a generic version of
Sanofi-Aventis (SASY.PA: ) and Bristol-Myers Squibb’s (BMY.N: )
heart drug Plavix, and it has said the drug would no longer be
seen as a core contributor.
($1=.7625 Euro)
(Editing by Hans Peters)

CORRECTED – Acino shares dip after Norwegian court ruling